贝纳利祖马布用于治疗多性炎带来的埃索诺菲尔粒状瘤症
Adrien Cottu1, Matthieu Groh2, Charlene Desaintjean3
1Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France.
Annals of the rheumatic diseases
|August 7, 2023
概括
贝纳利祖马布在治疗聚炎 (EGPA) 带来的埃索诺菲尔颗粒瘤症 (EGPA) 方面表现出有效性,特别是在耐火性喘和耳,耳,耳,鼻问题方面,从而减少了葡萄糖皮质类药物的使用. 然而,之前的梅波利祖马布治疗可能会降低本拉利祖马布的水平.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
背景情况:
- 贝纳利祖马布已被批准用于治疗埃索诺菲尔性喘,并正在研究其他由埃索诺菲尔驱动的疾病.
- 有限的数据存在于本拉利祖马布对以酸性颗粒炎与多炎 (EGPA) 的治疗.
研究的目的:
- 评估EGPA患者的非标签本拉利祖马布的疗效和安全性.
- 评估治疗响应率和葡萄糖皮质醇节约效应.
主要方法:
- 68名EGPA患者接受本拉利祖马布治疗的多中心回顾性研究.
- 主要终点:完全响应 (伯明翰血管炎活动评分=0,普雷尼松≤4毫克/天).
- 二级终点:部分反应 (伯明翰血管炎活动评分=0,普雷尼松≥4毫克/天).
主要成果:
- 49%的患者获得了完全反应,36%的患者获得了部分反应,15%的患者没有反应.
- 在38%的患者中断了葡萄糖皮质类药物治疗.
- 之前使用梅波利祖马布与更高的治疗失败和更少的葡萄糖皮质体类药物中止有关.
结论:
- 本拉利祖马布在EGPA中对耐火性喘/ENT症状有效,促进了葡萄糖皮质体减少.
- 在患者之前的梅波利祖马布治疗失败的情况下,本拉利祖马布的疗效可能会降低.
- 需要进一步的研究来优化本拉利祖马布在EGPA中的使用.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
346
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
346
Antiasthma Drugs: Leukotriene Modifiers
357
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
357
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Antiasthma Drugs: β2-Adrenoceptor Agonists
302
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
302
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Muscarinic Receptor Antagonists
340
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
340


